Given the current crisis, nearly all research has ground to a halt. We are unable to predict the length of disruption that will occur at this time but there will be likely knock-on delays. Many members of the teams at KCL, UCL and Imperial have been working from home, and will continue to do so for the foreseeable future. Other members of the Consortium, however, have been called to assist on the frontline in the fight against Covid-19. In addition, recruitment for Prostate Cancer Risk (Work strand 1) and Prostate Cancer Screening (Work strand 2) has been suspended at all sites in order to protect participants from any excess COVID-19 exposure.
As a prostate cancer survivor,
it is a privilege to be able to contribute to a study that has the potential to deliver new methods of testing for prostate cancer that are more reliable, more accurate and less invasive than the current prostate-specific antigen (PSA) test and biopsies. Not all men with prostate cancer are as fortunate as me; I had symptoms that indicated a problem, even though my PSA result was 'normal', but many men have no symptoms at all. We need a test that clinicians and patients can trust.
The ReIMAGINE consortium seeks to change forever the way in which prostate cancer is diagnosed, the manner in which it is classified, the method by which risk is communicated, the utility associated with the diagnosis, the benefit that is derived from intervention and reduce the overall costs of care.
The precise risk-stratification that results from an image-based measurable-disease approach will allow us to determine whether progression in prostate cancer is clonally specified or is a transitional phenomenon.
The risk stratification of prostate cancer that will emerge from ReIMAGINE will permit a departure from today’s one-size-fits-all approach towards an individualised care that matches the very broad risk profile of this ill understood disease.